CELL AND GENE THERAPY INSIGHTS

Filter by Interests

Filter by ContentType

Choosing the best path to patients: how to decide between in-house and outsourced iPSC therapy development and manufacturing

Choosing the best path to patients: how to decide between in-house and outsourced iPSC therapy development and manufacturing

Laura Koivusalo, Anni Mörö, Ross Macdonald
11 March 2025
Commentary
 Personalization in advanced cellular ImmunoTherapeutics: activities in Ireland

Personalization in advanced cellular ImmunoTherapeutics: activities in Ireland

Athanasios Mantalaris, Nicki Panoskaltsis, Fiona Killard
13 January 2025
Commentary
 De-risking pluripotent stem cell therapies

De-risking pluripotent stem cell therapies

Stephen Sullivan, Ricardo Baptista
18 June 2024
Commentary
 Unlocking the full potential of human induced pluripotent stem cells from haplo-selected cord blood samples—the how and the why

Unlocking the full potential of human induced pluripotent stem cells from haplo-selected cord blood samples—the how and the why

B Aran, D Morrow, E Rodriguez et al
14 February 2024
Commentary
 Innovation in cryopreservation & cold chain management

Innovation in cryopreservation & cold chain management

Barry Fuller, Roland Fleck, Glyn Stacey
22 November 2023
Commentary
 Cell and gene therapy commercial off-the-shelf software components

Cell and gene therapy commercial off-the-shelf software components

Parris Farr
23 August 2023
Commentary
 Critical success factors to consider before digitizing a cell & gene therapy supply chain

Critical success factors to consider before digitizing a cell & gene therapy supply chain

August Zepka, Charles Wilfong
23 July 2022
Commentary
 Regulatory & supply chain implications for plasmids as critical starting materials in the manufacture of viral vector gene therapy products

Regulatory & supply chain implications for plasmids as critical starting materials in the manufacture of viral vector gene therapy products

M Gosse, C Jones, D Jesus et al
08 March 2022
Commentary
 Challenges in qualification & management of raw materials in advanced therapy medicinal products

Challenges in qualification & management of raw materials in advanced therapy medicinal products

Shok Ping Lim, Sakina Gooljar
04 March 2022
Commentary
 Master ATMP processes by controlling raw and starting material

Master ATMP processes by controlling raw and starting material

Anne-Sophie Lebrun, Carmen Brenner
24 March 2021
Commentary
 Considerations for performing virtual quality audits on manufacturers of gene therapy viral vectors: an auditor’s perspective during the COVID-19 public health emergency

Considerations for performing virtual quality audits on manufacturers of gene therapy viral vectors: an auditor’s perspective during the COVID-19 public health emergency

Gary C du Moulin, PhD, MPH, RAC
18 March 2021
Commentary
 Small labels, big challenges: solutions for advanced therapy labeling

Small labels, big challenges: solutions for advanced therapy labeling

Heidi Hagen, Christophe Suchet
21 September 2020
Commentary
 The role of raw materials in the manufacturing of cell and gene therapy medicinal products: practices and challenges

The role of raw materials in the manufacturing of cell and gene therapy medicinal products: practices and challenges

José Caraballo
09 April 2020
Commentary